• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Kenvue Inc.

    6/2/25 4:27:41 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary
    Get the next $KVUE alert in real time by email
    SD 1 formsd-conflictsmineraldis.htm SD Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM SD
    SPECIALIZED DISCLOSURE REPORT
    Kenvue Inc.
     (Exact name of the registrant as specified in its charter)

    Delaware001-4169788-1032011
    (State or other jurisdiction
     of incorporation or organization)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)

    1 Kenvue Way
    Summit, New Jersey
    07901
    (Address of principal executive offices)(Zip Code)

    Meredith Stevens, (908) 874-1200
    (Name and telephone number, including area code, of the person to contact in connection with this report.)
    Check the appropriate box to indicate the rule pursuant to which this Form is being submitted, and provide the period to which the information in this Form applies:
    ☑    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.

    ☐    Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended _________.
        




    Section 1 – Conflict Minerals Disclosure 
    Item 1.01 Conflict Minerals Disclosure and Report 
    Conflict Minerals Disclosure 
    Kenvue, Inc. (together with its consolidated subsidiaries, “Kenvue”, “Company”, “we”, or “our”) hereby files this Form SD pursuant to Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”) for the reporting period from January 1, 2024 to December 31, 2024 (the “Reporting Period”). Please refer to Rule 13p-1, Form SD and the 1934 Act Release No. 34-67716 for definitions to the terms used in this Report, unless otherwise defined herein. A copy of this Form SD is also posted to the Company’s website at: https://investors.kenvue.com.
     The Rule generally provides that a company must file a specialized disclosure report if it manufactures or contracts to manufacture products for which one or more of the following minerals are necessary to the functionality or production of the company’s products: cassiterite; columbite-tantalite (coltan); and wolframite; their derivatives tantalum, tin, and tungsten; and gold (collectively, “3TGs”). These are considered “conflict minerals” under the Rule regardless of their geographic origin and whether or not they fund armed conflict in the Democratic Republic of the Congo or its neighboring countries (the “covered countries”).
    Kenvue is a global leader at the intersection of healthcare and consumer goods and the world’s largest pure-play consumer health company by revenue with $15.5 billion in Net sales in the fiscal year 2024. Our portfolio includes Self Care, Skin Health and Beauty, and Essential Health products. Our in-house manufacturing footprint delivered over 60% of our sales volume in 2024, with the remaining sales volume being supplied by an extensive global network of external manufacturing facilities (EMs) operated by third-party manufacturers. 
    Pursuant to the Rule, we conducted in good faith a technical review of Kenvue’s products and surveyed our suppliers and EMs for the calendar year 2024 to determine whether 3TGs were present in our products. Based on this survey, we identified three (3) EMs (the “Covered EMs”) that supplied materials or products containing 3TGs to Kenvue, where such materials or products were as applicable included in products manufactured by Kenvue or contracted to be manufactured for Kenvue and 3TGs were necessary to the functionality or production of such materials or products. These products fell into the category of one electronic device, an RFID smart label for one product, and one formulated product that contains gold.
    Reasonable Country of Origin Inquiry
    For those materials or products that contain 3TGs, we conducted in good faith a reasonable country of origin inquiry to determine whether any 3TG necessary to the functionality or production of these materials or products (i) originated in the covered countries or (ii) was not from recycled or scrap sources. For any materials or products containing 3TGs, Kenvue conducted direct outreach to the Covered EMs to gather information regarding the presence and sourcing of 3TG in its products manufactured during the Reporting Period.
    Each of the 3 Covered EMs provided a completed Conflict Minerals Reporting Template published by the Responsible Minerals Initiative (“CMRT”). In their completed CMRTs, all of the Covered EMs confirmed that the 3TGs were not sourced from the covered countries for the materials or products supplied to Kenvue.
    Based on the reasonable country of origin inquiry described above, Kenvue has no reason to believe that any of the 3TGs contained in our products manufactured during the Reporting Period, that are within the scope of the Rule, originated in the covered countries or were not from recycled or scrap sources.
    Item 1.02 Exhibit 
    Not applicable.
    Section 3 – Exhibits 
    Item 3.01 Exhibits 
    Not applicable.



    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
     
    KENVUE INC.
    Date: June 2, 2025By:/s/ Meredith Stevens
      
    Name:
    Title:
    Meredith Stevens
    Chief Operations Officer


    Get the next $KVUE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KVUE

    DatePrice TargetRatingAnalyst
    4/10/2025$23.50Neutral
    Redburn Atlantic
    3/24/2025$25.00In-line
    Evercore ISI
    1/6/2025$21.00 → $26.00Neutral → Overweight
    Piper Sandler
    12/12/2024$25.00 → $24.00Buy → Hold
    Deutsche Bank
    9/24/2024$27.00Buy
    Jefferies
    9/24/2024$24.00Outperform → Sector Perform
    RBC Capital Mkts
    5/28/2024$21.00Neutral
    Citigroup
    4/11/2024$18.00Underperform
    Bernstein
    More analyst ratings

    $KVUE
    Financials

    Live finance-specific insights

    See more
    • Kenvue Reports First Quarter 2025 Results

      Net Sales (3.9)%; Organic Sales1 (1.2)% Maintains Focus On Accelerating Profitable Growth and Optimizing Cost Structure, While Successfully Completing TSA Exits Updates Outlook for FY'25 for Incremental Tariff Costs and Currency Kenvue Inc. (NYSE:KVUE) today announced financial results for the first quarter ended March 30, 2025. "In Q1, our teams executed our plans while continuing to navigate an evolving macro and consumer environment," said Thibaut Mongon, Chief Executive Officer. "We are committed and focused on activating our brands while staying agile and flexible to accelerate sustainable profitable growth." First Quarter Summary Net sales decreased 3.9% vs the prior year p

      5/8/25 6:50:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue to Announce First Quarter 2025 Results on May 8, 2025

      Kenvue Inc. (NYSE:KVUE) will announce its first quarter 2025 financial results before market open on May 8, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine

      4/24/25 6:45:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue Declares Quarterly Cash Dividend

      Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on its common stock. This quarterly dividend is payable on May 28, 2025, to shareholders of record as of the close of business on May 14, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in

      4/16/25 8:19:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary

    $KVUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Redburn Atlantic initiated coverage on Kenvue with a new price target

      Redburn Atlantic initiated coverage of Kenvue with a rating of Neutral and set a new price target of $23.50

      4/10/25 12:41:58 PM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Evercore ISI initiated coverage on Kenvue with a new price target

      Evercore ISI initiated coverage of Kenvue with a rating of In-line and set a new price target of $25.00

      3/24/25 8:39:49 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Kenvue from Neutral to Overweight and set a new price target of $26.00 from $21.00 previously

      1/6/25 8:13:28 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary

    $KVUE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kenvue Debuts on Fortune 500 List

      Kenvue Inc. (NYSE:KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for the first time since becoming a fully independent company. With 2024 full year sales of $15.5 billion, Kenvue is listed at number 281. The company's debut is a testament to the power of its iconic brands and deep commitment to improving the health and well-being of consumers globally through science-backed, insights-led innovation. "Being named to the Fortune 500 list marks a significant milestone for Kenvue," said Thibaut Mongon, Chief Executive Officer. "Recognitions like this validate the hard work and dedication of our K

      6/2/25 6:15:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue Announces Participation in Deutsche Bank's dbAccess Global Consumer Conference

      Kenvue Inc. (NYSE:KVUE), the maker of iconic brands such as Neutrogena®, Listerine®, Aveeno®, and Tylenol®, today announced the Company's participation in Deutsche Bank's dbAccess Global Consumer Conference in Paris, France. Thibaut Mongon, Chief Executive Officer, Amit Banati, Chief Financial Officer, and Carlton Lawson, Group President, Europe, Middle East and Africa & Latin America will participate in a fireside chat on Tuesday, June 3, 2025, at 6:00 a.m. Eastern Time / 12:00 p.m. Central European Time. A live webcast of the session will be available on investors.kenvue.com and a replay will be available on the website following the event. About Kenvue Kenvue Inc. is the world's larges

      5/21/25 6:45:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Everyday Care in Action: Thousands of Kenvue Employees Come Together Across 21 Markets to Help Advance Healthier Communities

      Kenvuers contribute 5,000+ hours of volunteer time to local causes along with building 22,000+ hygiene kits for underserved communities Hygiene kits to feature 110,000+ donated products from iconic brands Neutrogena®, Listerine®, OGX®, Johnson's® Baby and more Kenvue Inc. (NYSE:KVUE), the maker of iconic brands such as Neutrogena®, Listerine®, Aveeno®, and Tylenol®, today announced its global community engagement efforts in celebration of Kenvue Cares Week, the company's signature annual volunteer initiative part of its Healthy Lives Mission. Kenvue Cares Week is a testament to the strong Kenvue commitment to advance the well-being of people and our planet, giving back through voluntee

      5/14/25 6:45:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary

    $KVUE
    SEC Filings

    See more
    • SEC Form SD filed by Kenvue Inc.

      SD - Kenvue Inc. (0001944048) (Filer)

      6/2/25 4:27:41 PM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Kenvue Inc. (0001944048) (Filer)

      5/27/25 4:26:08 PM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - Kenvue Inc. (0001944048) (Filer)

      5/22/25 4:31:52 PM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary

    $KVUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Corp. Affairs Officer Dyer Russell converted options into 2,669 shares and covered exercise/tax liability with 965 shares (SEC Form 4)

      4 - Kenvue Inc. (0001944048) (Issuer)

      6/5/25 4:27:00 PM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Chief Financial Officer Banati Amit

      4 - Kenvue Inc. (0001944048) (Issuer)

      6/4/25 4:35:13 PM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Director Smith Jeffrey C

      4 - Kenvue Inc. (0001944048) (Issuer)

      5/27/25 8:48:19 PM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary

    $KVUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

      SC 13G/A - Kenvue Inc. (0001944048) (Subject)

      11/14/24 1:22:40 PM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

      SC 13G/A - Kenvue Inc. (0001944048) (Subject)

      11/12/24 10:32:12 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

      SC 13G/A - Kenvue Inc. (0001944048) (Subject)

      10/16/24 10:07:52 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary

    $KVUE
    Leadership Updates

    Live Leadership Updates

    See more
    • Kenvue Debuts on Fortune 500 List

      Kenvue Inc. (NYSE:KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for the first time since becoming a fully independent company. With 2024 full year sales of $15.5 billion, Kenvue is listed at number 281. The company's debut is a testament to the power of its iconic brands and deep commitment to improving the health and well-being of consumers globally through science-backed, insights-led innovation. "Being named to the Fortune 500 list marks a significant milestone for Kenvue," said Thibaut Mongon, Chief Executive Officer. "Recognitions like this validate the hard work and dedication of our K

      6/2/25 6:15:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue Announces Chief Financial Officer Transition

      Amit Banati, 30-Year Consumer Products Company Finance and Operations Veteran, Appointed CFO Succeeds Paul Ruh, Effective May 12, 2025 Kenvue Inc. (NYSE:KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for overseeing the Finance and Strategy functions, supporting initiatives aimed at accelerating profitable growth and delivering value to shareholders. Following a thorough and thoughtful search process, Mr. Banati will succeed Paul Ruh, who will remain with the Company for a brief period to help ensure a smooth transition. Mr. Banati is a 30-year consumer products company finance and operation

      5/8/25 6:45:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue Announces Three New Appointments to Board of Directors

      Company and Starboard Value LP Enter into Cooperation Agreement Kenvue Inc. (NYSE:KVUE), the world's largest pure-play consumer health company by revenue, today announced the appointment of two new independent directors, Sarah Hofstetter, President of Profitero, Ltd., and Erica Mann, former President and Head of Bayer's Consumer Health Division, to the Company's Board of Directors (the "Board"). Additionally, Jeffrey Smith, Managing Member, Chief Executive Officer and Chief Investment Officer of Starboard Value LP (together with certain of its affiliates, "Starboard") will join the Board. All three appointments are effective immediately. "We are pleased to welcome Sarah, Erica and Jeff as

      3/5/25 8:05:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary